Adamis Pharmaceuticals Corp. (ADMP)

Adamis Pharmaceuticals Corp., an emerging biopharmaceutical company, is combining specialty pharmaceuticals and biotechnology to create treatment options in the areas of allergy, respiratory, oncology, and immunological disorders as well as for infectious diseases. With novel products and breakthrough science, the company has positioned itself to become a leader in the biopharmaceutical industry.

The company's current initiatives include the development of a prefilled single-dose epinephrine syringe for which a New Drug Application (NDA) has been submitted to the FDA. Adamis is also developing inhaled therapeutics for allergic rhinitis, asthma, and COPD under a December 2010 agreement with Beximco Pharmaceuticals Ltd., a Bangladesh conglomerate with over 400 products ranging from allergy to oncology.

Earlier this year, Adamis' biotechnology unit completed the acquisition of a novel technology forming the basis for a prostate cancer vaccine called TeloB-VAX. This technology is scheduled to enter Phase II studies. The vaccine platform may also be able to treat other tumor types, such as lung, breast, and colon cancers, as well as viral diseases, including chronic hepatitis, human papilloma virus (HPV), and influenza.

Adamis is led by a management team that retains considerable expertise in biotechnology, immunology, cancer management, and pharmaceutical research and development, among other medical fields. Members of the team have accumulated experience in executive corporate leadership and financial roles, coming from companies such as Citigroup Global Markets Inc. and Merrill Lynch.

Advanced Cell Technology, Inc. (ACTC)

Advanced Cell Technology, Inc. is a biotechnology company focused on developing cellular therapies for the treatment of diseases and conditions that impact tens of millions of people worldwide. By applying stem cell-based technologies and other proprietary methods in the field of regenerative medicine, the company aims to bring patient-specific therapies from the lab bench to the bedside.

Advanced Cell Technology currently has three cellular product platforms based on ground-breaking stem cell technology. As documented in the journals Nature and Cell Stem Cell, the company developed and holds in its repertoire the first-ever proven alternative method for successful hESC generation without harm to the embryo, called the "single-cell blastomere" technique, on which it holds broad patent protection.

The company is also focused on solving the problem of immune rejection and graft-versus-host disease by creating stem-cell therapeutics using donor tissues that are compatible so that they will not activate an immune response leading to rejection. The ability to create tissue cells for transplantation that have the same genetic make-up as the patient could create a significant revenue stream for Advanced Cell Technology.

In recent news, Advanced Cell Technology announced that the independent Data and Safety Monitoring Board (DSMB) overseeing its two ongoing stem cell clinical trials in the United States authorized the company to move forward with enrolling and treating the next set of patients in each of the trials. The unanimous recommendation of the DSMB to proceed with these trials represents a significant milestone. Management believes these trials will validate earlier pre-clinical findings.

Fibrocell Science, Inc. (FCSC)

Fibrocell Science, Inc. is a biotechnology company focused on the development of personalized autologous cell therapies for aesthetic, medical and scientific applications. The company's lead product, LAVIV (azficel-T), is the first and only personalized aesthetic cell therapy approved by the FDA for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

LAVIV involves an advanced process that extracts a person's fibroblast cells from a small skin sample and multiplies them in the Fibrocell Science lab. In normal skin, fibroblasts are responsible for producing collagen. LAVIV is the resulting formulation of a person's own fibroblast cells, which is then injected into wrinkles. Each person's formulation of LAVIV is unique because it is made from their own cells.

Last month, Fibrocell Science began the launch of LAVIV (azficel-T) in major metropolitan areas throughout the U.S. The company also launched mylaviv.com, a new resource for interested patient candidates. This website includes product information, frequently asked questions and will soon feature a physician finder, which will be continually updated as new physicians are trained and begin offering LAVIV in their practices.

David Pernock, Fibrocell Science Chairman and CEO, recently stated that the company will be offering LAVIV exclusively through board-certified dermatologists and plastic surgeons who have been trained by Fibrocell Science. Initially, the company will target select cities across the country and is on track to expand into other markets next year as more physicians are trained and manufacturing capacity increases.